{
    "Trade/Device Name(s)": [
        "B. anthracis Real-time PCR Assay"
    ],
    "Submitter Information": "Centers for Disease Control and Prevention",
    "510(k) Number": "K192871",
    "Predicate Device Reference 510(k) Number(s)": [
        "K140426"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NHT"
    ],
    "Summary Letter Date": "November 7, 2019",
    "Summary Letter Received Date": "October 8, 2019",
    "Submission Date": "October 7, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.3045"
    ],
    "Regulation Name(s)": [
        "In vitro diagnostic device for Bacillus spp. detection"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "virology"
    ],
    "Analyte(s)": [
        "B. anthracis chromosomal DNA",
        "B. anthracis pXO1 DNA",
        "B. anthracis pXO2 DNA"
    ],
    "Specimen Type(s)": [
        "Respiratory samples",
        "Whole blood",
        "Serum",
        "Plasma",
        "Swabs from lesions",
        "Cerebrospinal fluid",
        "Pleural fluid",
        "Bacterial culture isolates"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Sodium citrate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument",
        "Cepheid SmartCycler I",
        "Cepheid SmartCycler II",
        "QuantStudio Dx Real-Time PCR Instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Real-time PCR",
        "Nucleic acid amplification",
        "Fluorescent probe detection"
    ],
    "Methodologies": [
        "PCR"
    ],
    "Submission Type(s)": [
        "Assay",
        "Test"
    ],
    "Document Summary": "FDA 510(k) summary for CDC B. anthracis Real-time PCR Assay for qualitative detection of B. anthracis DNA in clinical specimens and bacterial isolates",
    "Indications for Use Summary": "Qualitative detection of plasmid and chromosomal DNA sequences from B. anthracis in human respiratory samples, whole blood, serum, plasma, lesion swabs, CSF, pleural fluid, and bacterial culture isolates from individuals suspected of anthrax; results are presumptive for direct specimen testing and should be used in conjunction with conventional methods for culture isolates as part of the LRN algorithm; limited to LRN designated laboratories.",
    "fda_folder": "Microbiology"
}